The Cambridge, Massachusetts-based company that developed a messenger RNA vaccine for Covid-19 may reveal multiple projects in China with a total investment size of around $1 billion, local media outlet Yicai reported Tuesday, citing sources it didn’t identify. The drugmaker is also actively seeking communication with Chinese regulators, it said, without providing more detail.
Chief Executive Officer
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.